Search results
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 7 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 4 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 3 days agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 4 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both...
Morningstar· 5 days agoJohnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in ...
Beese Fulmer Investment Management Inc. Sells 137 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 5 days agoBeese Fulmer Investment Management Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.6% during the first quarter, according to the company in its most recent 13F filing with ...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks· 6 days agoSkyrizi’s approval for the UC indication was based on data from two phase III studies, a 12-week induction study, INSPIRE1 and a 52-week maintenance study, COMMAND2. Skyrizi is already approved ...
Walking Helps Guard Against Recurrent Low Back Pain
Medscape· 5 days agoRegular walking can help prevent recurrent episodes of low back pain, a new study suggests. Among adults who recently recovered from an episode of low...
A New Psychotherapeutic 'Gold Standard' for Chronic Pain?
Medscape· 6 days agoA single course of treatment with emotional awareness and expression therapy (EAET) was associated...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 5 days agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque ...